CAS 219989-84-1|Ixempra|Aza-epothilone B|Ixabepilone|BMS-247550|Azaepothilone B|(1S,3S,7R,10S,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl...

基本信息

化学结构

分子式

C₂₇H₄₂N₂O₅S

分子量

506.69778

精确质量

506.28144345

电荷

InChI

InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17-,20-,21+,22-,24-,27+/m0/s1

InChIKey

FABUFPQFXZVHFB-CFWQTKTJSA-N

Canonic Smiles

O=C1N[C@@H](C[C@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C(=O)C([C@H](C1)O)(C)C)C)O)C)/C(=C/c1csc(n1)C)/C

Isomeric Smiles

s1cc(nc1C)/C=C(/[C@H]1NC(=O)C[C@H](O)C(C(=O)[C@@H]([C@@H](O)[C@H](CCC[C@]2(O[C@@H]2C1)C)C)C)(C)C)\C

计算属性

JChem

Acid pKa

13.84502

质子受体

质子供体

LogD (pH = 5.5)

3.392858

LogD (pH = 7.4)

3.393564

Log P

3.393573

摩尔折射率

136.7098

极化性

53.83667

极化表面积

112.05

可自由旋转的化学键

里宾斯基五规则

false

ALOGPS 2.1

Log P

3.28

LOG S

-5.16

溶解度

3.52e-03 g/l

数据来源

学术数据

数据来源

名称和标识

别名

Aza-epothilone BAzaepothilone BBMS-247550Ixabepilone

商标名

Ixempra

IUPAC标准名

(1S,3S,7R,10S,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione

IUPAC传统名

(1S,3S,7R,10S,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione

名称和标识

数据登录号

CAS号

219989-84-1

PubChem CID

23305354

PubChem SID

99443224160967821

数据登录号

化合物性质

暂无数据

点击上传数据

分子相关蛋白质

暂无数据

点击上传数据

分子图谱

暂无数据

点击上传数据

描述信息

DrugBank

DB04845

Drug Groups

approved; investigational

Description

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. [Wikipedia] Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that
minimizes susceptibility to esterase degradation.

Indication

Investigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).

Half Life

52 hours

Protein Binding

67-77%

Elimination

Mostly fecal and some renal.

External Links

• [Wikipedia]

描述信息

参考文献

PubChem文献

暂无数据